Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data
Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction. However, data for the safety of combinations are sparse.
|
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
In patients who have, or are at risk for, coronary artery disease, niacin added to statin therapy resulted in regression of the carotid intima–media thickness. In contrast...
|
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
A study compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure.
|
The Case for a Higher Maintenance Dose of Clopidogrel (Plavix)
Studies looking at increasing the loading dose of clopidogrel have been conducted over the past several years. This has lead to the current recommendation for a loading dose of up to 600 mg of clopidogrel in patients with acute coronary syndromes (ACS) before percutaneous coronary intervention (PCI).Now, there’s data focusing on doubling the maintenance dose
|
Use of Aldosterone Antagonists in Heart Failure
Clincial trials have established the incremental benefits of aldosterone antagonist therapy in patients with failure (HF) and reduced left ventricular ejection fraction (LVEF), such that aldosterone antagonists were designated as class I, “useful and recommended,” within the American College of Cardiology/American Heart Association (ACC/AHA) Chronic HF Guidelines.
|